New combo therapy shows promise for rare eye cancer
NCT ID NCT04552223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a combination of two drugs, nivolumab and relatlimab, can shrink tumors in people with metastatic uveal melanoma, a rare eye cancer that has spread. Twenty-seven participants received the treatment to see how many responded. The goal was to control the disease, not cure it, as ongoing management is typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States